Show simple item record

Rol de Infliximab en Enfermedad Inflamatoria Intestinal. Experiencia local

TREATMENT OF INFLAMMATORY BOWEL DISEASE WITH INFLIXIMAB. EXPERIENCE IN 25 PATIENTS

dc.contributores-ES
dc.contributoren-US
dc.creatorSimian, Daniela
dc.creatorQuijada, María Isabel
dc.creatorLubascher, Jaime
dc.creatorAcuña, Raúl
dc.creatorQuera, Rodrigo
dc.date2013-08-27
dc.date.accessioned2019-11-11T18:26:50Z
dc.date.available2019-11-11T18:26:50Z
dc.identifierhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/view/2612
dc.identifier.urihttps://revistaschilenas.uchile.cl/handle/2250/110870
dc.descriptionINTRODUCCIÓN: El tratamiento de la EII es complejo y su objetivo es lograr la remisión clínica, endoscópica y radiológica. La terapia biológica ha demostrado jugar un rol fundamental en el logro de estos. No obstante, aún existe una subindicación por temor a los eventos adversos asociados a su uso. OBJETIVOS: Describir el uso de Infliximab en pacientes con EII tratados en nuestra clínica durante los años 2007-2012, cuantificando su respuesta al tratamiento y la presencia de eventos adversos. MÉTODOS: Estudio descriptivo, sobre características clínicas, tratamiento y complicaciones. Se evaluó la respuesta posterior a la 2ª dosis, y a los 3-6 meses (control endoscópico/radiológico). RESULTADOS: Se incluyen 25 pacientes, 16 con Enfermedad de Crohn y nueve con Colitis Ulcerosa. Mediana edad 36 años (18-61). La indicación fue refractariedad a tratamiento en 13 pacientes, compromiso perianal en nueve, estenosis en dos y pioderma gangrenoso en uno. Diez pacientes iniciaron tratamiento cones-ES
dc.descriptionBackground: Biological therapy has an important role in the treatment of Inflammatory Bowel Disease (IBD). However, the use of these drugs is resisted due to fears about their side effects. Aim: To report the experience with the use of Infliximab in patients with IBD. Material and methods: Descriptive study of a historical cohort of patients with IBD treated between 2007 and 2012 with Infliximab.  A favorable clinical response was considered when general, intestinal and extra-intestinal symptoms subsided after the second or third dose of the drug. Endoscopic or imaging response was evaluated between three and six months of treatment. Results: Twenty five patients aged 18 to 61 years (12 women) were included. Sixteen had Cohn’s Disease and 9 had Ulcerative Colitis. Treatment was indicated due to refractory disease in 13 patients, perianal involvement in nine, stenosis in two and pyoderma gangrenosum in one. Ten patients initiated Infliximab within less than two years of diagnosis. Twenty-two patients received combined treatment with immunosuppressive medications and the other three patients were treated exclusively with Infliximab. A favorable clinical response was observed in 88% after the second dose and 64% had endoscopic or imaging remission after 3-6 months. Twelve patients discontinued Infliximab, due to bad response to treatment in three patients, economic cost in three patients, and patient/doctor decision in six. Only three patients had side effects (herpes zoster and sinusitis). None of these motivated the discontinuation of treatment. Conclusions: In this cohort of patients with IBD, the use of Infliximab was associated with endoscopic or imaging remission in 64% of cases after 3-6 months of treatment with no major side effects.en-US
dc.formatapplication/pdf
dc.languagespa
dc.publisherRevista Médica de Chilees-ES
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/view/2612/245
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/2612/8557
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/2612/8558
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/2612/8559
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/2612/8746
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/2612/8747
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/2612/10578
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/2612/10579
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/2612/10951
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/2612/10952
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/2612/10953
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/2612/10954
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/2612/10955
dc.sourceRevista Médica de Chile; Vol. 141, núm. 9 (2013): SEPTIEMBRE 2013es-ES
dc.source0034-9887
dc.subjectImmunotherapy; Biological Therapy; Infliximab; Ulcerative Colitis; Crohn´s Diseasees-ES
dc.subjectAntibodies, monoclonal; Colitis, ulcerative; Crohn disease; Infliximaben-US
dc.titleRol de Infliximab en Enfermedad Inflamatoria Intestinal. Experiencia locales-ES
dc.titleTREATMENT OF INFLAMMATORY BOWEL DISEASE WITH INFLIXIMAB. EXPERIENCE IN 25 PATIENTSen-US
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion
dc.typees-ES


This item appears in the following Collection(s)

Show simple item record